Prodrugs: A challenge for the drug development

Pharmacological Reports

Volumn 65, Issue 1, 2013, Pages 1-14

  Zawilska, Jolanta B ^a,b   Wojcieszak, Jakub ^b   Olejniczak, Agnieszka B ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

ADEPT; Blood brain barrier; Drugs' metabolism; GDEPT; Prodrugs

Indexed keywords

BAMBUTEROL; CAPECITABINE; CAPTOPRIL; CARBAMAZEPINE; ENALAPRIL MALEATE; ESTRAMUSTINE PHOSPHATE; FAMCICLOVIR; FLUDARABINE PHOSPHATE; FOSAMPRENAVIR; FOSPHENYTOIN SODIUM; FUNCTIONAL GROUP; GABAPENTIN; KETOROLAC; LATANOPROST; LEVODOPA; LOPERAMIDE 1 OXIDE; MOLSIDOMINE; NABUMETONE; ORGANOPHOSPHATE; OSELTAMIVIR; PREDNISOLONE SODIUM PHOSPHATE; PRIMIDONE; PRODRUG; SALAZOSULFAPYRIDINE; TENOFOVIR DISOPROXIL; TRAVOPROST; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; ZIDOVUDINE;

ACTIVE TRANSPORT; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; AQUEOUS SOLUTION; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TRANSFORMATION; DRUG TRANSPORT; EPILEPSY; ESTERIFICATION; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; LIPID SOLUBILITY; LIPOPHILICITY; ORGANOLEPTIC PROPERTY; PARKINSON DISEASE; PHOTODYNAMIC THERAPY; POSTHERPETIC NEURALGIA; PROCESS OPTIMIZATION; REVIEW; SOLID TUMOR; STRUCTURE ANALYSIS; SUSPENSION;

EID: 84875786061     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)70959-9     Document Type: Review

References (83)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ: Structure and function of the blood-brain barrier. Neurobiol Dis, 2010, 37, 13-25.
2. Afshar S, Asai T, Morrison SL, Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer. Mol Cancer Ther, 2009, 8, 185-193.
3. Albert A: Chemical aspects of selective toxicity. Nature, 1958, 182, 421-422.
4. Altaner C: Prodrug cancer gene therapy. Cancer Lett, 2008, 270, 191-201
5. Bagshawe KD: Targeting: the ADEPT story so far. Curr Drug Targets, 2009, 10, 152-157.
6. Baldwin A, Huang Z, Jounaidi Y, Waxman DJ: Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys, 2003, 409, 197-206.
7. Battah SH, Chee CE, Nakanishi H, Gerscher S, MacRobert AJ, Edwards C: Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy. Bioconjugate Chem, 2001, 12, 980-988.
8. Battah S, O'Neill S, Edwards C, Balaratnam S, Dobbin P, Mac-Robert AJ: Enhanced porphyrin accumulation using dendritic derivatives of 5-aminolaevulinic acid for photodynamic therapy: an in vitro study. Int J Biochem Cell Biol, 2006, 38, 1382-1392.
9. Bean GW, Camras CB: Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol, 2008, 53, Suppl 1, S69-84.
10. Beaumont K, Webster R, Gardner I, Dack K, Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr Drug Metab, 2003, 4, 461-485.
11. Berger Y: Evaluation of dipeptide-derivatives of 5-aminolevulinic acid as precursors for photosensitizers in photodynamic therapy. Bioorg Med Chem, 2003, 11, 1343-1351.
12. Bertolini A, Ferreri A, Guerzoni S, Tacchi R, Leone S: Paracetamol: New vista of an old drug. CNS Drug Rev, 2006, 12, 250-275.
13. Bhandari KH, Newa M, Yoon SI, Kim JS, Jang KY, Kim JA, Yoo BK et al.: Evaluation of physicochemical properties, skin permeation and accumulation profiles of ketorolac fatty ester prodrugs. Biol Pharm Bull, 2007, 30, 2211-2216.
14. Bissonnette R, Tremblay J, Juzenas P, Boushira M, Lui H: Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques. J Invest Dermatol, 2002, 119, 77-83.
15. Bobeck DR, Schinazi RF, Coats SJ: Advances in nucleoside monophosphate prodrugs as anti-HCV agents. Antivir Ther, 2010, 15, 935-950.
16. Charkoudian LK, Pham DM, Franz KJ: A prochelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J Am Chem Soc, 2006, 128, 12424-12425.
17. Chen L, Waxman DJ: Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des, 2002, 8,1405-1416.
18. Chen X, Wu B, Wang PG: Glucuronides in anti-cancer therapy. Curr Med Chem Anti-cancer Agents, 2003, 3, 139-150.
19. Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV: Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules, 2009, 14, 4517-4545.
20. Das N, Dhanawat M, Dash B, Nagarwal RC, Shrivastava SK: Codrug: An efficient approach for drug optimization. Eur J Pharm Sci, 2010, 41, 571-588.
21. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ: Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA, 2008, 105, 17356-17361.
22. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, Sinko PJ et al.: Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA, 2005, 102, 12962-12967.
23. Di Stefano A, Sozio P, Cerasa LS: Antiparkinsonian prodrugs. Molecules, 2008, 13, 46-68.
24. Di Venosa GM, Casas AG, Battah S, Dobbin P, Fukuda H, Macrobert AJ, Batlle A: Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy. Int J Biochem Cell Biol, 2006, 38, 82-91.
25. Divaris DX, Kennedy JC, Pottier RH: Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol, 1990, 136, 891-897.
26. Fasinu P, Pillay V, Ndesendo VMK, de Toit LC, Choonara YE: Diverse approaches for the enhancement of oral drug bioavailability. Biopharm Drug Dispos, 2011, 32, 185-209.
27. Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ: In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther, 2000, 7, 1738-1743.
28. Gaullier J, Berg K, Peng Q, Anholt H, Selbo P, Ma L, Moan J: Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. J Cancer Res, 1997, 57, 1481-1486.
29. Girardin F: Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci, 2006, 8, 311-321.
30. Graf N, Lippard SJL: Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv Drug Deliv Rev, 2012, 64, 993-1004.
31. Gynther M, Laine K, Ropponen J, Leppänen J, Mannila A, Nevalainen T, Savolainen J et al.: Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem, 2008, 51, 932-936.
32. Hatanaka T, Haramura M, Fei YJ, Miyauchi S, Bridges CC, Ganapathy PS, Smith SB et al.: Transport of amino acid-based prodrugs by the Na+- and Cl-coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther, 2004, 308, 1138-1147.
33. He G, Massarella J, Ward P: Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet, 1999, 37, 471-484.
34. Hughes BW, King SA, Allan PW, Parker WB, Sorscher EJ: Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase. J Biol Chem, 1998, 273, 2322-2328.
35. Huttunen KM, Raunio H, Rautio J: Prodrugs - from serendipity to rational design. Pharmacol Rev, 2011, 63, 750-771.
36. Jana S, Mandlekar S, Marathe P: Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Curr Med Chem, 2010, 17, 3874-3908.
37. Johnston PG, Kaye S: Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs, 2001, 12, 639-646.
38. Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, González S: Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol, 2008, 10, 148-154.
39. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs, 2000, 59, 1233-1250.
40. Khatri A, Russell PJ: Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer. Discov Med, 2007, 7, 39-45.
41. Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S: Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials, 2010, 31, 4592-4599.
42. Kokil GR, Rewatkar PV: Bioprecursor prodrugs: molecular modification of the active principle. Mini Rev Med Chem, 2010, 10, 1316-1330.
43. Koukourakis GV, Kouloulias V, Koukourakis MJ, Zacharias GA, Zabatis H, Kouvaris J: Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules, 2008, 13, 1897-1922.
44. Li F, Maag H, Alfredson T: Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci, 2008, 97, 1109-1134.
45. Mahato R, Tai W, Cheng K: Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev, 2011, 63, 659-670.
46. Martiniello-Wilks R, Wang XY, Voeks DJ, Dane A, Shaw JM, Mortensen E, Both GW, Russell PJ: Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med, 2004, 6, 1343-1357.
47. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N et al.: Design of a novel oral fluoro-pyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 1998, 34, 1274-1281.
48. Müller CE: Prodrug administration for enhancing the bioavailability of drugs with low molecular solubility. Chem Diver, 2009, 6, 2071-2083.
49. Musiol R, Serda M, Polanski J: Prodrugs in photodynamic anticancer therapy. Curr Pharm Des, 2011, 17, 3548-3559.
50. Pardridge WM: Brain drug development and brain drug targeting. Pharm Res, 2007, 24, 1729-1732.
51. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF: Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs, 2009, 23, 35-58.
52. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M: 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer, 1997, 79, 2282-2308.
53. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O'Grady J et al.: Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother, 2000; 44, 2811-2815.
54. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, Savolainen J: Prodrugs: design and clinical applications. Nat Rev Drug Discov, 2008, 7, 255-270.
55. Rautio J, Laine K, Gynther M, Savolainen J: Prodrug approaches for CNS delivery. AAPS J, 2008, 10, 92-102.
56. Rodriguez L, Batlle A, Di Venosa G, Battah S, Dobbin P, Macrobert AJ, Casas A: Mechanisms of 5-aminolevulinic acid ester uptake in mammalian cells. Br J Pharmacol, 2006, 147, 825-833.
57. Rogers LM, McGivern PG, Butler AR, MacRobert AJ, Eggleston IM: An efficient synthesis of 5-aminolaevulinic acid (ala)-containing peptides for use in photodynamic therapy. Tetrahedron, 2005, 61, 6951-6918.
58. Salvetti A: Newer ACE inhibitors. A look at the future. Drugs, 1990, 40, 800-828.
59. Schellmann N, Deckert PM, Bachran D, Fuchs H, Bachran C: Targeted enzyme prodrug therapies. Mini Rev Med Chem, 2010, 10, 887-904.
60. Schukin SI, Zinkovsky VG, Zhuk OV: Elimination kinetics of the novel prodrug cinazepam possessing psychotropic activity in mice. Pharmacol Rep, 2011, 63, 1093-1100.
61. Shi Y, Liu S-A, Kerwood DJ, Goodisman J, Dabrowiak JC: Pt(IV) complexes as prodrugs for cisplatin. J Inorg Biochem, 2012, 107, 6-14.
62. Sievers EL: Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis, 2003, 31, 7-10.
63. Silverman R.: The Organic Chemistry of Drug Design and Drug Action. 2nd edn., Elsevier Academic Press, Burlington, 2004.
64. Singh PP, Joshi S, Russell PJ, Verma ND, Wang X, Khatri A: Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer. Clin Cancer Res, 2011, 17, 4006-4018.
65. Sofia MJ: Nucleotide prodrugs for HCV therapy. Antivir Chem Chemother, 2011, 22, 23-49.
66. Song X, Lorenzi PL, Landowski CP, Vig BS, Hilfinger JM, Amidon GL: Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm, 2005, 2, 157-167.
67. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J: Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother, 1995, 39, 2759-2764.
68. Springer CJ, Niculescu-Duvaz I.: Prodrug-activating systems in suicide gene therapy. J Clin Invest, 2000, 105, 1161-1167.
69. Srinivas NR: The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges. Eur J Drug Metab Pharmacokinet, 2011, 36, 49-59.
70. Stella VJ: Prodrugs: some thoughts and current issues. J Pharm Sci, 2010, 99, 4755-4765.
71. Stella VJ, Burchardt RT, Hageman MJ, Oliyai R, Maah H, Tilley JW: Prodrugs: Challenges and Rewards. Part 1, Springer, New York, 2007.
72. Teicher BA, Chari RV: Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res, 2011, 17, 6389-6397.
73. Teicher BA: Antibody-drug conjugate targets. Curr Cancer Drug Targets, 2009, 9, 982-1004.
74. Testa B: Prodrugs; bridging pharmacodynamic/pharmacokinetic gaps. Curr Opin Chem Biol, 2009, 13, 338-344.
75. Tietze LF, Krewer B: Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. Chem Biol Drug Des, 2009, 74, 205-211.
76. Tsume Y, Vig BS, Sun J, Landowski CP, Hilfinger JM, Ramachandran C, Amidon GL: Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules, 2008, 13, 1441-1454.
77. Umapathy NS, Ganapathy V, Ganapathy ME: Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB0,+. Pharm Res, 2004, 21, 1303-1310.
78. Vytla D, Combs-Bachmann RE, Hussey AM, McCarron ST, McCarthy DS, Chambers JJ: Prodrug approaches to reduce hyperexcitation in the CNS. Adv Drug Deliv Rev, 2012, 64, 666-685.
79. Wu K-M: A new classification of prodrugs: regulatory perspective. Pharmaceuticals, 2009, 2, 77-81.
80. Yaltho TC, Ondo WG: The use of gabapentin enacarbil in the treatment of restless legs syndrome. Ther Adv Neurol Disord, 2010, 3, 269-275.
81. Yu C, Hu Y, Duan J, Yuan W, Wang C, Xu H, Yang XD: Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One, 2011, 6, e24077.
82. Zhang Y, Chen Y, Han D, Ocsoy I, Tan W: Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis, 2010, 2, 907-918.
83. Zhang Y, Hong H, Cai W: Tumor-targeted drug delivery with aptamers. Curr Med Chem, 2011, 18, 4185-4194.